IVERIC bio Inc

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that President and Chief Executive Officer Christine Ann Miller has been elected to the Board of Directors of IVERIC bio, Inc. (Nasdaq: ISEE), effective immediately. Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with

Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced today the election of Christine Ann Miller to its Board of Directors, effective immediately.

Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors

NEW YORK--(BUSINESS WIRE)--Iveric Bio will participate in the H.C. Wainwright BioConnect Virtual Conference, being held virtually from January 10-13, 2022.

Iveric Bio to Present at the H.C. Wainwright BioConnect Virtual Conference

IVERIC bio (ISEE) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

IVERIC bio (ISEE) is on the Move, Here's Why the Trend Could be Sustainable

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the appointment of Tony Gibney to Executive Vice President and Chief Business and Strategy Officer, effective December 13, 2021.

Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer

Bicycle Therapeutics Plc - ADR

BioNTech SE

Avid Bioservices

Enanta Pharmaceuticals

Moderna

Prothena

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

7 A-Rated Biotechs to Buy for the Long Run

NEW YORK--(BUSINESS WIRE)--Iveric announced that Glenn P. Sblendorio, CEO, and Pravin Dugel, M.D., President, will participate in the Stifel 2021 Virtual Healthcare Conference.

Iveric Bio to Participate in the Stifel 2021 Virtual Healthcare Conference

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the quarter ended September 30, 2021 and provided a general business update.

Iveric Bio Reports Third Quarter 2021 Operational Highlights and Financial Results

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that the Company will participate in a fireside chat at the Credit Suisse 30th Annual Virtual Healthcare Conference on Nov. 9.

Iveric Bio to Participate in the Credit Suisse 30th Annual Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its third quarter 2021 financial and operating results on Tuesday, November 9, 2021.

Iveric Bio to Report Third Quarter 2021 Financial Results and Host Conference Call on Tuesday, November 9, 2021

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at $16.75 per share to the public.

Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock

Iveric Bio is developing Zimura - indicated for Geographic Atrophy - an eye disease that often leads to blindness.

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

The stock price of IVERIC bio Inc (NASDAQ: ISEE) increased 62.49% yesterday. This is why it happened.

ISEE Stock: Why It Significantly Increased Yesterday

NEW YORK--(BUSINESS WIRE)--Iveric announced that Pravin Dugel, M.D., President, will present an overview of the Company at the 2021 H.C. Wainwright Global Investment Conference.

Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.

Here's Why Iveric Bio Stock Is Rocketing Higher Today

IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today. The post ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is a Boon to IVERIC bio appeared first on InvestorPlace.

ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is a Boon to IVERIC bio

IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Friday after Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported results from its Phase 3 DERBY and OAKS studies in geographic atrophy. Apellis said the Phase 3 DERBY study in geographic atrophy did not meet the primary endpoint of GA lesion growth.

Why IVERIC Bio Shares Are Soaring Today

Iveric Bio Inc (NASDAQ:ISEE) stock is trading almost 50% higher as the investors are cheering Stifel's initiated coverage on Iveric Bio with a Buy rating and a price target of $22.00. Analyst Annabel Samimy comments that, though the Company is not a first mover in the still untapped Geographic Atrophy (GA) market, Iveric could very well be the leading treatment for this indication.

Why Are Iveric Bio Shares Surging In Premarket Friday?

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

Implied Volatility Surging for IVERIC bio (ISEE) Stock Options

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that the Company will participate in the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17 2021.

Iveric Bio to Present at the H.C. Wainwright Ophthalmology Virtual Conference

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that Pravin U. Dugel, M.D., President, will participate in a panel at the Wedbush Conference on Wed., Aug. 11 at 8:00 a.m. ET.

Iveric Bio to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the quarter ended June 30, 2021 and provided a general business update.

Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021.

News for IVERIC bio Inc Stock (ISEE)